Q1 2025 BioMarin Pharmaceutical Inc Earnings Call Transcript
Key Points
- Biomarin Pharmaceutical Inc (BMRN) reported a strong financial performance with a 15% revenue growth in the first quarter of 2025.
- Non-GAAP earnings per share increased by 59% year-over-year, highlighting significant profitability expansion.
- VOXZOGO's global revenue reached $214 million, marking a 40% increase year-over-year.
- The company completed enrollment in its pivotal Phase III study with VOXZOGO in children with hypochondroplasia, aiming for a potential launch in 2027.
- Biomarin Pharmaceutical Inc (BMRN) has a strong global presence, with approximately 2/3 of its total revenues originating from outside the United States, providing insulation from potential US tariffs.
- There is uncertainty regarding potential pharmaceutical tariffs, which could impact Biomarin Pharmaceutical Inc (BMRN)'s financials if imposed.
- VOXZOGO's revenue growth in the first half of 2025 is expected to be lower due to global order dynamics, with more substantial growth anticipated in the second half.
- Non-GAAP SG&A expenses are expected to increase throughout 2025 as the company invests in strategic priorities, potentially impacting operating margins.
- The company faces long-term competition concerns for VOXZOGO, particularly beyond 2030.
- There are challenges in correlating VOXZOGO's PK data with growth outcomes, which could impact the development of BMN 333.
Good day, everyone, and welcome to the BioMarin Pharmaceutical first-quarter 2025 conference call. Just a reminder that this conference is being recorded. I would now like to hand things over to Ms. Traci McCarty. Please go ahead, ma'am.
Thank you, operator. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.
In addition, we will use non-GAAP financial measures as defined in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
